Media Centre

  • 07 Jun 2016
    - Highlights

    EBE webinar live from BIO: "Accessing the European Market: What Do You Need to Know and When Do You Need to Know It?"

    June 8th, 2016 - 17-18h CET, 8-9h PDT (California)

    A spotlight on the specifics for cell, gene and tissue therapy

    Watch the webinar here 

     
     
    Read more |
  • 12 May 2016
    - Highlights

    Podcast with Eduardo Bravo – TiGenix - and Samantha Parker – Lysogene - on Adoption of New technologies

    Facing the current challenges of coming to market with new ATMPs in Europe, particularly from the standpoint of the barriers to Adoption; this podcast aims to explore in depth several of the topics around funding and commercialising ATMP technologies in Europe.

    Theme:

    Europe is producing excellent ATMP technologies, but there are many barriers to reaching patients and surviving in the market and the EU is starting to bleed promising technology companies to the United States, what does Europe need to do to fix this problem?

    Topics:

    1) What are some EU ATMP technologies that are showing promise, or have been commercialised?
    2) Give an overview of the current EU funding situation moving from Phase II to Phase III; "the valley of death"
    3) How is the situation around reimbursement in Europe developing? What are the core problems? Does the hospital exemption help or hurt?
    4)What are some tangible actions that should be taken to arrest the "brain drain" of promissing SMEs working in Europe?

    Check out the podcast here.

    Read more |
  • 22 Feb 2016
    - Press Release

    EuropaBio and EBE host a multi-stakeholder debate on the labelling of biosimilar medicines

    On 2 February 2016, EuropaBio, the European Association for Bio Industries, and EBE, the European Biopharmaceutical Enterprises, jointly facilitated a multi-stakeholder workshop in Brussels on the labelling of biosimilar medicinal products. 40 people participated in the meeting, including representatives of EU and national associations of patients, physicians and pharmacists. Three representatives from the European Medicines Agency (EMA) attended the meeting as observers. 

    Update 3 May 2016: Meeting summary available for download

     

    Read more | Download Document (531.82 kB)